RxDoctor Payments Data

Mary States

Acute Care · San Diego, CANPI 1699748657

Payments from drug & device makers

$1,555in general payments, 2019–2025

Across 59 payments — averaging $26.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$379
  • Amgen$228
  • Novartis$227
  • Lilly USA, LLC$193
  • AbbVie$174
  • Abbott$145
  • plus $210 from 7 others

What the payments were for

  • Food & beverage$1,555100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,555 in reported general payments places this provider in the 80th percentile of 1,153 acute care providers in California.

See all acute care providers in California

Medicare billing

Part B allowed, 2024
$12,575
Medicare patients
71
Services billed
150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$21,655
MounjaroTirzepatide12$18,296
SynthroidLevothyroxine Sodium29$2,478
PaxlovidNirmatrelvir/Ritonavir13$1,429
Metoprolol Succinate26$552
Lidocaine11$495
Losartan Potassium31$493
Celecoxib12$332
Metformin Hcl ErMetformin Hcl20$262
Ezetimibe11$251
Atorvastatin Calcium19$240
Levothyroxine Sodium14$188
Amlodipine Besylate14$185
Pantoprazole Sodium16$176
ValacyclovirValacyclovir Hcl14$155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$76$23,08430 claims
Lilly USA, LLCMounjaro$193$18,29612 claims
AbbVieSynthroid$174$2,47829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,153 acute care providers in California.

Other acute care in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →